Menopausal hormone therapy and breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 142, Issue , 2014, Pages 52-61

  Santen, Richard J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Breast cancer; Estradiol; Mechanisms; Menopausal hormone therapy; Progestogen

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ARTICLE; ATTRIBUTABLE RISK; BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; DOSE RESPONSE; ESTROGEN BLOOD LEVEL; FEMALE; GROUPS BY AGE; HUMAN; KINETICS; MAMMOGRAPHY; MENOPAUSAL HORMONE THERAPY; MENOPAUSE; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM;

EQUIDAE;

BREAST CANCER; ESTRADIOL; MECHANISMS; MENOPAUSAL HORMONE THERAPY; PROGESTOGEN;

ADULT; AGED; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MAMMOGRAPHY; MENOPAUSE; MIDDLE AGED; RISK; TIME FACTORS; WOMEN'S HEALTH;

EID: 84899915554     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.06.010     Document Type: Article

References (84)

1. T.L. Bush, M. Whiteman, and J.A. Flaws Hormone replacement therapy and breast cancer: a qualitative review Obstetrics & Gynecology 98 3 2001 498 508 (Review)
2. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer Lancet 350 9084 1997 1047 1059 (see comment; erratum appears in Lancet 1997 Nov 15;350(9089):1484)
3. J.E. Rossouw, G.L. Anderson, and R.L. Prentice et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women's Health Initiative randomized controlled trial Journal of the American Medical Association 288 3 2002 321 333 (see comment)
4. M.L. Stefanick, G.L. Anderson, and K.L. Margolis et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy Journal of the American Medical Association 295 14 2006 1647 1657
5. V.M. Barnabei, B.B. Cochrane, and A.K. Aragaki et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative Obstetrics & Gynecology 105 5:Pt 1 2005 t-73
6. Anonymous. UK. Public Assessment Report Hormone-Replacement Therapy. Safety update.
7. M. Clemons, and P. Goss Estrogen and the risk of breast cancer New England Journal of Medicine 344 4 2001 276 285 (erratum appears in N Engl J Med 2001 Jun 7;344(23):1804; Review)
8. J.D. Yager, and N.E. Davidson Estrogen carcinogenesis in breast cancer New England Journal of Medicine 354 3 2006 270 282 (see comment; Review)
9. M. Feinleib Breast cancer and artificial menopause: a cohort study 776 Journal of the National Cancer Institute 41 2 1968 315 329
10. D. Trichopoulos, B. MacMahon, and P. Cole Menopause and breast cancer risk Journal of the National Cancer Institute 48 3 1972 605 613
11. N.F. Boyd, H. Guo, and L.J. Martin et al. Mammographic density and the risk and detection of breast cancer New England Journal of Medicine 356 3 2007 227 236
12. T. Key, P. Appleby, I. Barnes, and G. Reeves Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies 828 Journal of the National Cancer Institute 94 8 2002 606 616
13. R. Kaaks, S. Rinaldi, and T.J. Key et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition 72 Endocrine-Related Cancer 12 4 2005 1071 1082
14. R.J. Santen, D.C. Allred, and S.P. Ardoin et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement Journal of Clinical Endocrinology & Metabolism 95 7 Suppl. 1 2010 Suppl-Sus. 66 (Review)
15. R.J. Santen, N.F. Boyd, and R.T. Chlebowski et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model 400 Endocrine-Related Cancer 14 2 2007 169 187
16. J.D. Yager, and R. Santen Mechanisms relating estrogen to breast cancer Translational Endocrinology and Metabolism 3 1 2012 75 93
17. E. Cavalieri, D. Chakravarti, and J. Guttenplan et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention Biochimica et Biophysica Acta 1766 1 2006 63 78 (Review)
18. M.L. Mello, B.C. Vidal, I.H. Russo, M.H. Lareef, and J. Russo DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182,780 as assessed by image analysis Mutation Research 617 1-2 2007 1 7
19. M. Saeed, E. Rogan, S.V. Fernandez, F. Sheriff, J. Russo, and E. Cavalieri Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol International Journal of Cancer 120 8 2007 1821 1824
20. J. Russo, and I.H. Russo The role of estrogen in the initiation of breast cancer Journal of Steroid Biochemistry & Molecular Biology 102 1-5 2006 89 96 (Review)
21. G.A. Balogh, I.H. Russo, B.R. Balsara, and J. Russo Detection of chromosomal aberrations by comparative genomic hybridization during transformation of human breast epithelial cells in vitro International Journal of Oncology 29 4 2006 877 881
22. W. Yue, J.P. Wang, and Y. Li et al. Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms International Journal of Cancer 127 8 2010 1748 1757
23. E.G. Rogan, A.F. Badawi, and P.D. Devanesan et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer Carcinogenesis 24 4 2003 697 702
24. N.W. Gaikwad, L. Yang, and S. Pruthi et al. Urine biomarkers of risk in the molecular etiology of breast cancer Breast Cancer 3 2009 1 8
25. N.W. Gaikwad, L. Yang, and P. Muti et al. The molecular etiology of breast cancer: evidence from biomarkers of risk International Journal of Cancer 122 9 2008 1949 1957
26. B.J. Fuhrman, C. Schairer, and M.H. Gail et al. Estrogen metabolism and risk of breast cancer in postmenopausal women Journal of the National Cancer Institute 104 4 2012 326 339
27. R.T. Chlebowski, G.L. Anderson, and M. Gass et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women Journal of the American Medical Association 304 15 2010 1684 1692
28. R.E. James, A. Lukanova, and L. Dossus et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study Cancer Prevention Research 4 10 2011 1626 1635
29. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674 (Review)
30. L.D. Wood, D.W. Parsons, and S. Jones et al. The genomic landscapes of human breast and colorectal cancers Science 318 5853 2007 1108 1113
31. A.Z. LaCroix, R.T. Chlebowski, and J.E. Manson et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial Journal of the American Medical Association 305 13 2011 1305 1314
32. R.J. Santen Risk of breast cancer with progestins: critical assessment of current data Steroids 68 10-13 2003 953 964 (Review)
33. L.J. Hofseth, A.M. Raafat, J.R. Osuch, D.R. Pathak, C.A. Slomski, and S.Z. Haslam Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast Journal of Clinical Endocrinology & Metabolism 84 12 1999 4559 4565
34. K.B. Horwitz, and C.A. Sartorius Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis Journal of Clinical Endocrinology & Metabolism 93 9 2008 3295 3298
35. Z. Huang, S.E. Hankinson, and G.A. Colditz et al. Dual effects of weight and weight gain on breast cancer risk Journal of the American Medical Association 278 17 1997 1407 1411
36. K.A. Brown, and E.R. Simpson Obesity and breast cancer: progress to understanding the relationship Cancer Research 70 1 2010 4 7 (Review)
37. C. Pichard, Plu-Bureau, Neves-E Castro, and A. Gompel Insulin resistance, obesity and breast cancer risk Maturitas 60 1 2008 19 30 (Review)
38. S.S. Tworoger, B.A. Rosner, and W.W. Hankinson SE The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: a nested case control study Breast Cancer Research 13 2011 R99
39. M.A. Blankenstein, I. Maitimu-Smeele, G.H. Donker, J. Daroszewski, A. Milewicz, and J.H. Thijssen On the significance of in situ production of oestrogens in human breast cancer tissue Journal of Steroid Biochemistry & Molecular Biology 41 3-8 1992 891 896
40. A. Lipton, S.J. Santner, and R.J. Santen et al. Aromatase activity in primary and metastatic human breast cancer Cancer 59 4 1987 779 782
41. A.A. Larionov, L.M. Berstein, and W.R. Miller Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues Journal of Steroid Biochemistry & Molecular Biology 81 1 2002 57 64
42. M.J. Reed, P.A. Beranek, M.W. Ghilchik, and V.H. James Estrogen production and metabolism in normal postmenopausal women and postmenopausal women with breast or endometrial cancer European Journal of Cancer & Clinical Oncology 22 11 1986 1395 1400
43. P.E. Lonning, H. Helle, N.K. Duong, D. Ekse, T. Aas, and J. Geisler Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status Journal of Steroid Biochemistry & Molecular Biology 117 13 2009 31 41
44. B.P. Haynes, A.H. Straume, and J. Geisler et al. Intratumoral estrogen disposition in breast cancer Clinical Cancer Research 16 6 2010 1790 1801
45. A.K. Dunbier, H. Anderson, and Z. Ghazoui et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women Journal of Clinical Oncology 28 7 2010 1161 1167
46. G.A. Greendale, B.A. Reboussin, S. Slone, C. Wasilauskas, M.C. Pike, and G. Ursin Postmenopausal hormone therapy and change in mammographic density Journal of the National Cancer Institute 95 1 2003 30 37 (see comment)
47. K. Ghosh, K.R. Brandt, and C. Reynolds et al. Tissue composition of mammographically dense and non-dense breast tissue Breast Cancer Research & Treatment 131 1 2012 267 275
48. B.A. Swiglo, M.H. Murad, and H.J. Schunemann et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system Journal of Clinical Endocrinology & Metabolism 93 3 2008 666 673
49. V.M. Montori GRADE: A System for Assessing Level of Evidence 2009
50. R.J. Santen, and G.R. Petroni Relative versus attributable risk of breast cancer from estrogen replacement therapy Journal of Clinical Endocrinology & Metabolism 84 6 1999 1875 1881 (Review)
51. G.L. Anderson, M. Limacher, and A.R. Assaf et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial Journal of the American Medical Association 291 14 2004 1701 1712 (see comment)
52. G.L. Anderson, R.T. Chlebowski, and J.E. Rossouw et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin Maturitas 55 2 2006 103 115
53. R.T. Chlebowski, S.L. Hendrix, and R.D. Langer et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial Journal of the American Medical Association 289 24 2003 3243 3253 (see comment)
54. R.T. Chlebowski, L.H. Kuller, and R.L. Prentice et al. Breast cancer after use of estrogen plus progestin in postmenopausal women New England Journal of Medicine 360 6 2009 573 587
55. R.L. Prentice, R.T. Chlebowski, and M.L. Stefanick et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women American Journal of Epidemiology 167 10 2008 1207 1216 (see comment)
56. R.L. Prentice Women's health initiative studies of postmenopausal breast cancer Advances in Experimental Medicine & Biology 617 2008 151 160 (Review)
57. J.A. Collins, J.M. Blake, and P.G. Crosignani Breast cancer risk with postmenopausal hormonal treatment Human Reproduction Update 11 6 2005 545 560 (see comment; erratum appears in Hum Reprod Update. 2006 May-Jun;12(3):331; Review)
58. G.K. Reeves, V. Beral, J. Green, T. Gathani, D. Bull, and S.C. Million Women Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and metaanalysis Lancet Oncology 7 11 2006 910 918 (see comment)
59. V. Beral, and S.C. Million Women Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 9382 2003 419 427 (see comment; erratum appears in Lancet. 2003 Oct 4;362(9390):1160)
60. C.J. Crandall, A. Karlamangla, M.H. Huang, G. Ursin, M. Guan, and G.A. Greendale Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy Archives of Internal Medicine 166 15 2006 1578 1584 (erratum appears in Arch Intern Med. 2006 Nov 13;166(20):2176)
61. K. Bakken, A. Fournier, and E. Lund et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition International Journal of Cancer 128 1 2011 144 156
62. A. Fournier Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? Journal of Clinical Oncology 2009 online publication Sept 14, 2009
63. Y.Y.W.W.J.S.R. Song The effect of a tissue specific estrogen complex (TSEC) on breast cancer xenografts in mice: rationale for use of a tissue selective complex Proceedings of the Endocrine Society 2012 (abstract)
64. C.E. Wood, T.B. Clarkson, and H. Chen et al. Comparative effects of oral conjugated equine estrogens and micronized 17beta-estradiol on breast proliferation: a retrospective analysis Menopause 15 5 2008 890 898
65. A. Gompel Plu-Bureau. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Annals of the New York Academy of Sciences 1205 2010 268 276 (Review)
66. S.A. Tsai, M.L. Stefanick, and R.S. Stafford Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009 Menopause 18 4 2011 385 392
67. A.S. Robbins, and C.A. Clarke Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004 Journal of Clinical Oncology 25 23 2007 3437 3439
68. K. Canfell, E. Banks, and M. Clements et al. Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003 Breast Cancer Research & Treatment 117 3 2009 671 673
69. R.M. Martin What was the immediate impact on population health of the recent fall in hormone replacement therapy prescribing in England/Ecological Study. Wheeler BW MCGD, editor Journal of Public Health 2010 10.1093/pubmed/fdq021 Advance Access
70. P.M. Ravdin, K.A. Cronin, and N. Howlader et al. The decrease in breast-cancer incidence in 2003 in the United States New England Journal of Medicine 356 16 2007 1670 1674 (see comment)
71. A. Gompel, and R.J. Santen Hormone therapy and breast cancer risk 10 years after the WHI Climacteric 15 3 2012 241 249
72. D.W. Sturdee, A. Pines, and International Menopause Society Writing Group et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health Climacteric 14 3 2011 302 320
73. S.L. Bailey, B.M. Sigal, and S.K. Plevritis A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years Journal of the National Cancer Institute 102 16 2010 12631271
74. R.J. Santen, W. Yue, and D.F. Heitjan Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy Cancer Epidemiology, Biomarkers & Prevention 21 7 2012 1038 1048
75. R.X. Song, G. Mor, and F. Naftolin et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol [see comment] Journal of the National Cancer Institute 93 22 2001 1714 1723
76. R.X. Song, Z. Zhang, G. Mor, and R.J. Santen Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells Apoptosis 10 3 2005 667 678
77. R.X. Song, and R.J. Santen Apoptotic action of estrogen Apoptosis 8 1 2003 55 60 (Review)
78. J.S. Lewis, K. Meeke, and C. Osipo et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation Journal of the National Cancer Institute 97 23 2005 1746 1759
79. J. Suckling, A. Lethaby, and R. Kennedy oestrogen for vaginal atrophy in postmenopausal women Cochrane Database of Systematic Reviews 2006 4 2003 CD001500 (update of Cochrane Database Syst Rev. 2003;(4):CD001500; PMID: 14583935; Review)
80. G. Schmidt, S.B. Andersson, O. Nordle, C.J. Johansson, and P.O. Gunnarsson Release of 17-betaoestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation Gynecologic & Obstetric Investigation 38 4 1994 253 260
81. I.S. Fraser, R. Ayton, E. Farrell, E. Weisberg, G. Darling, and A. Murkies A multicentre Australian trial of low dose estradiol therapy for symptoms of vaginal atrophy using a vaginal ring as delivery system Maturitas 22 Suppl. 1995
82. A. Kendall, M. Dowsett, E. Folkerd, and I. Smith Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Annals of Oncology 17 4 2006 584 587
83. E. Amir, O.C. Freedman, B. Seruga, and D.G. Evans Assessing women at high risk of breast cancer: a review of risk assessment models [Review] Journal of the National Cancer Institute 102 10 2010 680 691
84. N.F. Boyd, J.W. Byng, and R.A. Jong et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study Journal of the National Cancer Institute 87 9 1995 670 675